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Abstract 
Abdominal aortic aneurysm (AAA) is a local expansion of the abdominal aorta wall caused 
by a complex multifactorial maladaptive vascular remodeling. Despite recent advances in the 
management of cardiovascular diseases, there currently is no established drug therapy for 
AAA. Since the probability of death from a ruptured AAA still remains high, preventive 
elective repair of AAAs larger than 5.5 cm in luminal diameter is considered the best 
treatment option. However, perioperative complications are problematic as elective AAA 
repair comes with numerous intrinsic risks. Impelled by the need of improving AAA therapy, 
significant efforts have been made to identify pharmacological tools that would slow down 
AAA enlargement and lower the risk of rupture, thereby reducing the necessity of surgical 
intervention. In this review, we discuss recent findings addressing molecular targets that 
could potentially treat AAA, particularly addressing: statins, classical renin angiotensin 
system (RAS) blockers, the protective arm of RAS, renin inhibitors, tetracyclines, 
interleukin-1β inhibition, anti-angiogenic agents and urocortins.  
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Introduction 
Abdominal aortic aneurysm (AAA) is a local enlargement of the arterial wall caused by a 
complex maladaptive vascular remodeling, which affects a large portion of the elderly 
population [1]. AAA development involves different integrated factors such as biomechanical 
forces, inflammatory cell infiltrates and the production and activation of various proteases 
and cytokines. Nevertheless the underlying mechanisms are poorly known [2].   
In an early stage of AAA the elastic fibers are degraded by proteases produced by vascular 
smooth muscle cells and infiltrating macrophages [3]. Consequently, inflammatory cytokines 
are released leading to an increase in leukocyte infiltration and intensification of proteolytic 
enzymes production, which potentiates the extracellular matrix disruption [2]. In addition to 
this process, smooth muscle cells are depleted, contributing to arterial wall weakening [2, 4, 
5]. Moreover, a chronic mural thrombus might be formed, intensifying the inflammatory 
process and contributing to disease progression [2]. These structural changes in the arterial 
wall do not only lead to the local enlargement of the vessel, but may also cause its rupture 
when the arterial wall can no longer withstand the arterial blood pressure [1, 5].  
Despite recent advances in the management of cardiovascular diseases, there is currently no 
established drug therapy for AAA, and preventive elective repair of AAAs larger than 5.5 cm 
in luminal diameter is considered as the best option since the probability of death from 
rupture still remains significant [6]. Nonetheless, perioperative complications of elective 
AAA repair are problematic and present considerable risks [7]. Therefore, motivated by the 
great need of improving AAA therapy, significant efforts have been made to identify new 
molecular targets and/or pharmacological tools that would slow down the rate of AAA 
expansion and reduce the risk of rupture [7, 8], thereby reducing the necessity of surgical 
intervention, which would be a meaningful improvement for the patients.  
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Here, we will discuss the current literature that focuses on potential molecular targets and/or 
pharmacological tools aimed for treating AAA. In particular, we will detail the statins, 
classical renin angiotensin system (RAS) blockers, the protective arm of RAS, renin 
inhibitors, tetracyclines, interleukin-1β inhibition, anti-angiogenic agents and Urocortins. 
 
Statins 
Statins are currently used to lower cholesterol levels by inhibiting the enzyme 3-hydroxy-3-
methylglutaryl coenzyme A reductase, a central enzyme involved in the production of 
cholesterol [9]. These drugs are extensively used to prevent atherosclerosis progression and 
to significantly reduce the risk of adverse events [9]. Numerous studies indicate 
hyperlipidemia as key factor in the development of AAA [10]; however, there is no clear 
evidence linking this relationship and recent data supports a contradictory view [7]. In spite 
of this, statins have been indicated as a potential tool to treat AAA based on its pleiotrophic 
effects on inflammation, oxidative stress and extracellular matrix composition, which causes 
reduction of AAA, independent of their cholesterol-lowering effect [11]. Steinmetz and co-
authors showed that simvastatin suppresses the development of AAA induced by transient 
elastase perfusion of the abdominal aorta in both normal and hypercholesterolemic mice [12]. 
The mechanism of action was independent of lipid reduction and involved a decline in matrix 
metalloproteinase (MMP)-9 expression, an increase in expression of tissue inhibitor of 
metalloproteinase (TIMP)-1, and preservation of the medial elastin and smooth muscle cells 
in the aortic wall [12]. Similarly, simvastatin was shown to prevent and reduce AAA growth 
in a rabbit model based on aorta exposition to CaCl2 [13]. These beneficial effects were 
associated with a reduction in MMP-2 and MMP-9 expression [13]. Nagashima and co-
workers examined the effect of cerivastatin on MMP-9 production in the aneurysmal wall 
organ isolated from patients with infrarenal AAA. They found that cerivastatin significantly 
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reduced the tissue levels of both total and active MMP-9 in a concentration-dependent 
manner [14]. Using aortic biopsies from patients that underwent elective open repair of AAA, 
simvastatin given pre-operatively reduced MMP-9 levels in the aneurysmal wall [15]. 
Interestingly, in a cohort of 150 patients monitored over 3 years, an association was observed 
between statin use and a decrease in expansion rate of infrarenal aortic aneurysms [16]. 
Similarly, other cohorts also reported a decrease in AAA growth following treatment with 
statins [17, 18].  
Contrary to these data, no association was reported between prescription statin and AAA 
expansion in a cohort of 652 patients undergoing surveillance of small AAA [19]. Moreover, 
different meta-analyses have achieved inconsistent outcomes regarding the beneficial actions 
of statins on AAA [20-22]. 
Overall several studies suggest that statins are promising drugs for the treatment of AAA, but 
further controlled randomized studies are needed to establish a more complete understanding 
of the effect of statins in AAA treatment. 
 
Renin Angiotensin System - Classical System 
The renin angiotensin system (RAS) is a major regulator of the cardiovascular system and has 
critical role in the pathophysiology of several diseases, including AAA [5, 23]. Angiotensin 
(Ang) II, the main RAS effector, is fundamentally important for cardiovascular homeostasis, 
but its hyperactivity is associated with several cardiovascular diseases [24, 25]. Ang II is 
mainly formed by the angiotensin-converting enzyme (ACE) and invokes deleterious actions, 
mostly via activation of the AT1 receptor [23, 24].  Remarkably, Ang II infusion in low-
density lipoprotein receptor (Ldlr
-/-
) or apolipoprotein E (ApoE
-/-
) gene deleted mice is 
sufficient to induce AAA-like dilatation of the abdominal aorta [26-28] (re-defined as 
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dissecting abdominal aortic aneurysm [29, 30]), highlighting a central role of Ang II in the 
pathogenesis of AAA [5]. Based on these and other observations, the pharmacological 
blockage of Ang II, by inhibition of angiotensin-converting enzyme (ACE) or blockage of 
AT1 receptors, has emerged as a potential tool to prevent AAA growth and/or reduce the risk 
of rupture [5]. In different studies, Ang II-induced dissecting AAA formation in ApoE
-/-
 mice 
was prevented by AT1 receptor blockers (ARBs) or ACE inhibitors (ACEi) [31, 32]. Such 
outcomes were predictable, especially for ARBs, since the dissecting AAA model was based 
on Ang II hyperactivity. Nevertheless, the beneficial effects of these drugs against dissecting 
AAA were not restricted to the Ang II-induced model. ARBs and ACEi significantly 
ameliorated AAA in different animal models, including AAA-induction by intra-aortic 
infusion of porcine pancreatic elastase and in a DOCA-salt model associated to degeneration 
of elastic lamina by b-aminopropionitrile infusion, both of which are AAA models 
independent of Ang II infusion [33-36].  
Ang II induces dissecting AAA by modulating different molecular mechanisms. Interestingly, 
Ang II provokes dissecting AAA in hypercholesterolemic mice, independent of increases in 
blood pressure [37]. In the early stage of dissecting AAA development, Ang II has been 
shown to contribute to infiltration and accumulation of macrophages in the sub intima, 
mainly by stimulating CCL2 (also known as MCP-1) secretion from endothelial and vascular 
smooth muscle cells [38-40]. Additional inflammatory pathways are also involved in the 
action of Ang II. Some evidence has suggested that CCL5 also has an important role in Ang 
II induced dissecting AAA [41]. Moreover, Ang II may stimulate the expression of 
cyclooxygenase-2 (COX-2) [42, 43], a critical enzyme in AAA pathogenesis that forms 
vasoactive and inflammatory prostaglandins. Indeed, it has been shown that COX-2 
deficiency attenuates Ang II infusion-mediated dissecting AAA [44]. Ang II also may 
stimulate osteopontin (OPN) secretion and actions [45]. OPN is a secreted extracellular 
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structural protein with pleiotropic functions that have been implicated in tissue repair, 
remodeling, and inflammation which also has an important role in AAA [45]. OPN acts as a 
chemotactic cytokine and modulates adhesion, migration, and activation of macrophages 
[46].  
Ang II also intensifies dissecting AAA evolution in mice by stimulating the production and 
activity of MMPs with consequent degradation of the arterial wall integrity [47, 48]. Indeed, 
doxycycline, a broad specificity inhibitor of MMPs, attenuates the incidence and severity of 
dissecting AAA induced by Ang II infusion [49]. Similarly, MMP-2-deficiency is known to 
inhibit Ang II induced elastin degradation in ApoE-/- mice [50].  
Another important mechanism triggered by Ang II stimulus is the hyper-production of 
oxidative stress [51]. Numerous studies have demonstrated Ang II as a potent stimulator of 
reactive oxygen species (ROS) in a variety of disorders [23]. ROS overproduction leads to an 
increased inflammatory profile, MMP activation and smooth muscle cell apoptosis, 
potentiating AAA development [52]. Interestingly, treatment with vitamin E, an antioxidant 
agent, ameliorates dissecting AAA formation in Ang II-infused ApoE-/- mice [53]. 
Accordingly, it was shown that Ang II-derived ROS triggers nuclear translocation of the 
AMP-activated protein kinase, a central energy-sensing enzyme that monitors cellular energy 
status, resulting in aberrant expression of MMP2, extracellular matrix degradation and 
consequent AAA worsening [50].  
Taken together, the evidence strongly suggest that RAS acts as a key player in the 
pathogenesis of dissecting AAA in mice, suggesting that compounds that target this system 
could be potential tools to inhibit AAA progression and/or prevent AAA rupture. However, 
most information is based on angiotensin II-infused mice which show dissection-like features 
that are not reproduced in human AAA [29, 38] . Information from clinical trials is limited, 
especially regarding the effectiveness of ACEi and ARBs. The latter is indispensable if and 
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when such drugs were to be considered for clinical treatment of AAA. A new clinical trial 
might, however, provide these critical data. In an ongoing phase 4 study, the effectiveness of 
Telmisartan in slowing down the progression of abdominal aortic aneurysms and reducing the 
circulating concentrations of AAA biomarkers is being investigated in comparison to placebo 
(ClinicalTrials.gov number NCT01683084).  
 
The Protective Arm of RAS - ACE2/Ang-(1-7)/Mas receptor 
In the classical paradigm, the RAS actions are triggered by a sequence of enzymatic reactions 
that is generated by Ang II. This enzymatic cascade is initiated by renin, which breaks down 
the precursor angiotensinogen to Ang I, an inactive decapeptide. Sequentially, ACE cleaves 
Ang I and forms the octapeptide Ang II. Ang II exerts its biological effects via activation of 
two distinct G protein-coupled receptors, AT1 and AT2, but the deleterious actions of Ang II 
are mediated by AT1 receptors [23]. In fact, the relevance of Ang II/AT1 is evidenced by the 
remarkable success obtained by drugs based on the pharmacological inhibition of ACE and 
blockage of AT1 receptors, which are frontline treatment options for hypertension. Contrary 
to the AT1 receptor, activation of the AT2 receptor appears to provide beneficial actions, such 
as vasodilation, antiproliferative and anti-inflammatory actions, thus counter-regulating the 
AT1 receptor effects [54-56]. Despite the fact that actions triggered by AT1 prevail over 
counter-actions triggered by AT2, the stimulation of the AT2 receptor apparently contributes 
to the beneficial actions produced by AT1 receptor blockers, suggesting that selective AT2 
agonists may be used as potential tools for the treatment of cardiovascular disease [54, 57], 
including AAA [31, 58]. Indeed, there is evidence that AT2 activation produces beneficial 
anti-AAA outcomes. For instance, co-infusion of Ang II and PD123319 (an AT2 receptor 
antagonist) in ApoE-/- mice significantly worsened AAA, suggesting a protective action 
mediated by AT2 [31]. Similarly, AT2-gene deletion enhances the abnormal growth and 
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rupture of the aorta in a mouse model of Marfan syndrome [58]. Contrarily, other reports 
have shown that AT2 deficiency does not affect Ang II-induced AAA in LDL
-/-
 mice while 
PD123319 augments AAA through a mechanism that is AT2 receptor independent [59]. Such 
conflicting data could be explained by the different backgrounds of the used animals and the 
poor selectivity of PD123319, since this compound can also block the MrgD receptor for 
alamandine [60].  
Taken together, emerging data suggest that selective AT2 agonists may be effective for 
treating AAA. However, due to the conflicting and limited data, the role of AT2 on AAA and 
efficacy of selective AT2 agonists must be further evaluated.  
In 2000, an important component of the RAS has been discovered, the angiotensin converting 
enzyme 2 (ACE2) [61, 62]. This enzyme breaks down Ang II to form Ang-(1-7), a 
heptapeptide with actions often contrary to those of Ang II [63-65]. Ang-(1-7), which binds 
to its own receptor, the Mas GPCR, induces many protective actions, such as vasodilation, 
reduction of oxidative stress, and anti-inflammatory and antithrombotic effects [64, 66]. 
Therefore, ACE2 is a key player that regulates the balance of an Ang II and Ang-(1-7), a 
deleterious and protective effector [64, 66]. Based on that, ACE2 has emerged as a potential 
target to treat cardiovascular diseases, including AAA. Thatcher and co-workers have shown 
that ACE2 is detectable in murine and human AAAs [67]. Moreover, they observed that 
ACE2 deficiency worsens dissecting AAA in the mouse model based on Ang II infusion [67]. 
Interestingly, diminazene aceturate, an ACE2 activator compound, ameliorates and markedly 
reduces the incidence of dissecting AAA in Ang II-infused mice, suggesting that ACE2 could 
be a potential target in the treatment of AAA and identifies diminazene as a possible 
pharmacological tool [67]. Despite these exciting findings, the potential of ACE2 and 
effectivity of diminazene or other ACE2 activator compounds must be confirmed.  
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Renin Inhibition 
Beyond the previously mentioned strategies that target RAS, another key component of this 
system has been developed. Aliskiren is the first representative of a new class drugs based on 
the inhibition of renin, thereby focusing on an upstream RAS mediator [68]. Recently, Seto 
and co-authors showed that aliskiren significantly inhibits the expansion of the dissecting 
AAA diameter in the Ang II-infused ApoE
-/-
 mouse model, as assessed by ultrasound [69]. 
This effect was associated with a reduction in T-lymphocytes and macrophages infiltration in 
the aorta wall [69]. Moreover, it caused a reduction in pro-renin receptor expression and 
mitogen-activated protein kinase (MAPK) activity in the suprarenal aorta [69]. A clinical trial 
aimed at addressing the anti-inflammatory effect of aliskiren in patients with small AAA and 
mild hypertension was initiated at the end of 2011; however, the trial was terminated due to 
an insufficient number of participants (ClinicalTrials.gov number NCT01425242). Overall, 
renin inhibition appears to present interesting outcomes against AAA; however, the necessary 
scientific support remains limited.  
 
Tetracycline 
The modulation of extracellular matrix composition is fundamental in the maintenance of the 
vascular wall integrity [47]. MMPs are the major enzymes in the vascular remodeling, and 
over-activity of such enzymes is closely associated to AAA pathogenesis and progression 
[47, 70]. Based on the relevance of MMPs on AAA, doxycycline emerged as a potential tool 
for the treatment of AAA. This antibiotic agent, member of the tetracycline antibiotic class, is 
listed as one of the most important medications needed for basic health in the World Health 
Organization's List of Essential Medicines. However, its protective effects against AAA are 
not related to its antibiotic activity, but to the inhibition of MMPs [8]. The effectivity of 
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doxycycline against AAA was first shown in a rat model of AAA, induced by elastase 
perfusion. Doxycycline treatment reduced the incidence and diameter of AAA, which was 
associated with a reduction in aortic elastin degradation without altering the influx of 
inflammatory cells [71]. Doxycycline was also effective in inhibiting AAA growth in other 
AAA animal models, such as aneurysm induced by bathing the periadventitial aortic with 
CaCl2 [72] or dissecting AAA induced by Ang II infusion in ApoE-/- mice [49, 73]. It has 
been shown that chemically modified tetracyclines without antibiotic activity exhibited 
similar efficacy to that of doxycycline by inhibiting AAA growth and disrupting the medial 
elastin in a rat model of AAA, induced by elastase perfusion [74]. Contradictory to these 
studies, Lida et al reported that doxycycline does not influence aneurysm progression in two 
different AAA animal models, Ang II-infused ApoE
-/-
 mice or transient intra-aortic porcine 
pancreatic elastase infusion in B6 mice [33]. Similarly, Xie showed that doxycycline did not 
affect dissecting AAA progression and aortic rupture in Ang II-infused mice [75].   
To better evaluate the effects of doxycycline against AAA, a number of studies have 
addressed the action of doxycycline in human AAA. It has been documented that 
preoperative doxycycline treatment (for 7 days) in patients who underwent elective repair of 
an infrarenal AAA, reduced MMP-9 expression and post-translational processing of MMP-2 
in aneurysmal tissues [76]. Interestingly, in a prospective phase II study (cohort n=36), 
Baxter and co-workers demonstrated that prolonged treatment (6 month) with doxycycline 
promoted a gradual reduction of MMP-9 plasma levels compared to baseline levels in 
patients with small asymptomatic AAAs [77]. In a randomized, double-blind, placebo-
controlled pilot study, the effectivity of doxycycline was evaluated in patients (cohort n=32) 
with AAA growth larger than 30 mm but less than 55 mm. The aneurysm expansion rate in 
the doxycycline group was significantly lower than in the placebo group during the 6-12 
month and 12-18 month period [78]. However, a large imbalance in the randomization of 
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smoking patients (smoking patients: doxycycline group 3/17, 17.6%; placebo group 8/15, 
53.3%, [78]) may represent an important concern for the interpretation of these results, due to 
the fact that smoking is one of the most prevalent risk factors for AAA development and 
progression [79].  
Most of the reports focused on the expression/activity of MMP-9 and MMP-2 when 
evaluating the actions of doxycycline on AAA [80]; moreover, other MMPs types and 
additional mechanism appear to be involved. Apparently, doxycycline also reduces the 
expression of MMP-3 and MMP-25 in aortic aneurysmal tissue [81]. Furthermore, this 
compound enhances Cystatin C and TIMP-1, important MMP inhibitors [81]. Beyond 
regulating the major extracellular matrix modulators, doxycycline also produced a significant 
and selective suppression of aortic wall inflammation by reducing neutrophil infiltration, as 
well as cytotoxic T-cell and vascular cytokines [82].  
Contrarily to these studies, a recent randomized clinical trial did not observe any influence of 
doxycycline on small AAAs [83]. In a cohort of 286 patients, which represents a larger 
database than previous studies, small AAAs were monitored under doxycycline or placebo 
treatment for 18 months. Surprisingly, an increased aneurysm growth in patients receiving 
doxycycline was observed, while the need of elective surgery was similar between the 
doxycycline and the placebo group [83].  These controversial data may be explained by the 
different doses used in the studies (Mosorin et at 150mg/day [78] ; Meijer et al 100mg/day 
[83]). An ongoing randomized controlled double-blind clinical trial using a higher dose (100 
mg twice a day) may provide additional information regarding the effectivity of doxycycline.    
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Interleukin-1 
Interleukin-1 (IL-1) is a key cytokine in the inflammatory cascade [84] and is a central factor 
and powerful modulator of AAA genesis and progression [85-87]. Production of IL1β was 
significantly higher in aneurysmal tissues than control aortic tissue from cadaveric donors 
[87]. Similarly, the circulating IL1β was markedly increased in patients with AAA [86]. 
These findings strongly suggest that IL1β is involved in the pathogenesis of AAA. In fact, 
Johnston et al demonstrated that IL-1β expression was elevated in the abdominal aorta of B6 
mice after elastase aortic perfusion [85]. Moreover, IL1β- or IL1R-gene deficiency protected 
against elastase perfusion-induced AAA formation, which is associated with a reduction in 
macrophage and neutrophil infiltration, as well as elastin preservation [85]. In the same study, 
pretreatment with Anakinra, an IL1R antagonist, significantly inhibited AAA enlargement, 
macrophage infiltration and elastin disruption [85]. Together, these findings suggest 
IL1β/IL1R is a potential target for the pharmacological treatment of AAA. Currently, a 
multicenter, randomized, double-blind, placebo-controlled phase II clinical trial 
(ClinicalTrials.gov number NCT02007252) aims to assess the safety, tolerability and efficacy 
of ACZ885 on aneurysmal growth rate in 100 patients with AAA. ACZ885, named 
Canakinumab, is a human monoclonal antibody targeted at interleukin-1 beta. The outcome 
of this trial may provide valuable insights for the pharmacological treatment for AAA. 
 
Anti-angiogenic therapy 
The use of anti-angiogenic agents for the treatment of AAA has been speculated recently 
based on evidence demonstrating that exacerbated angiogenesis in human and animal AAA 
wall may contribute to the initiation and progression of aneurysm [88]. Different studies have 
shown an intense neovascularization in the aneurysmal aortic walls of human and animal 
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models. Holmes et al performed a morphometric analysis in human aortic aneurysmatic 
tissues and observed an augmented medial neovascularization compared to normal aortas 
[89]. Similarly, another study documented increased angiogenesis in all layers (media, 
adventitia and a transition zone) of the human aortic aneurysmal wall. The same study also 
reported that the degree of neovascularization in the AAA was highly correlated with the 
amount of the inflammatory cell infiltration [90], suggesting an association between the 
angiogenesis and cell infiltration. Performing histological analyses in human AAA biopsies, 
Kobayashi et al observed that the augmented neovascularization in the aneurysmatic walls 
was associated with augmented vascular endothelial growth factor (VEGF) expression in the 
infiltrated area [91], suggesting that the neoangiogenesis within the AAA wall is driven by 
VEGF overexpression, a potent angiogenic factor. In accordance with that, recombinant 
human VEGF treatment intensified the formation of Ang II-induced dissecting AAAs in 
ApoE-/- mice [92].  
The studies mentioned above point out angiogenesis as a critical mechanism in the 
pathogenesis of AAA, contributing to the increase of cell infiltration and consequent 
degeneration of the aortic wall. Additionally, beyond its critical role in the initiation of 
aneurysm, evidence indicates that angiogenesis also modulates the ongoing process of mature 
aortic aneurysm, contributing to the expansion and rupture of aortic wall [93]. Indeed, Choke 
et al found that biopsy samples from aneurysm rupture edge displayed increased medial 
neovascularization compared to the aneurysm wall at the level of rupture (region 3 cm away 
from the rupture edge) and from the anterior sac. Moreover, they observed that the aneurysm 
rupture edge displayed an increased expression of proangiogenic cytokines (αv-integrin, 
VEGF, VE-cadherin, MCP-1, and vimentin) [94]. Thus the focal increase in medial 
neovascularization in the aneurysm rupture edge, with a concomitant increase in 
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proangiogenic expression, may contribute to the aneurysm rupture; however, further 
investigations are necessary to confirm this hypothesis.  
The use of anti-angiogenic drugs has been approved for the treatment of numerous diseases. 
In fact, this drug class is a landmark for the treatment of different modalities of cancer [95]. 
Based on the critical role of angiogenic pathways in human AAAs, anti-angiogenic drugs 
may therefore also represent a potential tool to reduce the progression of the aneurysms and 
diminish the risk rupture. In this line, VEGF, one of the most potent angiogenic and vascular 
permeability factors, has been pointed out by different groups as a potential target for such 
compounds against AAA. Evidence has shown a critical role of VEGF in the 
pathophysiology of AAA. For instance, it was documented that the intensity of angiogenesis 
in human aortic aneurysmal was associated to a larger amount of infiltrated inflammatory 
cells expression VEGF [91]. Moreover, recombinant human VEGF treatment increased the 
formation of Ang II-induced aneurysms in ApoE-/- mice [89, 96]. In accordance, treatment 
with the soluble form of VEGF-A receptor-1 (negative modulator of VEGF) reduced 
aneurysm size, restored wavy structure of the elastic lamellae, reduced cell infiltration, 
attenuated MMP activity and decreased neoangiogenesis in an animal model of AAA induced 
by periaortic application of CaCl2 [96]. Together, these results suggest that pharmacological 
compounds able to block VEGF may be beneficial for AAA treatment. Currently, drugs that 
block VEGF actions are readily available in the clinic. These drugs are used in the treatment 
of certain cancers and in age-related macular degeneration. However, so far, no study has 
explored the action of these drugs against AAA. Controversially, a case report has inferred 
that intravitreal injection of bevacizumab, a recombinant monoclonal anti-VEGF-A, was 
associated with AAA rupture {Baek, 2014 #105}. While this is of course a single case, this 
evidence calls for further investigation.  
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Urocortin 2  
Urocortins (UCN) are hormones members of the corticotropin-releasing hormone family that 
have an essential role in the central system and peripheral tissues [97]. In the last years, 
UCNs emerged as critical modulators of the cardiovascular system and relevant efforts have 
been engaged to explore its peripheral actions [97]. These endogenous hormones are peptides 
with 38 to 40 aminoacids that act through activation of two distinguished G-protein-coupled 
receptors (GPCR), corticotrophin-releasing factor receptor (CRFR) type 1 and type 2. Three 
isoforms of UNCs have been described, UCN1, UCN2 and UCN3; interestingly, they exhibit 
different affinity to the CRFRs. While UCN1 binds to both CRFR1 and CRFR2, UCN2 and 
UCN3 show selectively binding to the CRFR2 [98]. CRFR1 and CRFR2 are expressed in the 
central system and periphery. However, the actions of CRFR2 predominate in the 
cardiovascular system [97, 98]. 
Various studies in humans and animals have shown the implication of UCNs in different 
cardiovascular disorders, such as atherosclerosis, myocardial infarct and heart failure [97, 99, 
100]; however, its role on AAA has only been reported very recently [101, 102]. The first 
evidence associating the UCNs to AAA was documented by Rush et al [102]. Using the Ang 
II-infused ApoE-/- mouse AAA model, they investigated genes that were differentially 
expressed in the aneurysm prone segment of aorta. Interestingly, UCN3 gene expression was 
downregulated in the suprarenal region of the aorta (susceptive to aneurysm formation in 
mice) compared to the infrarenal region (resistant to aneurysm formation in mice)[102], 
raising the speculation that UCNs have a protective function against AAA. In another study, 
the same group reported that UCN2 and CRFR2 gene expression were significantly higher in 
the most dilated part of the human AAA compared to the non-dilated proximal neck of the 
AAA [101]. Moreover, in a well-controlled cohort they also documented that UCN2 plasma 
level was higher in AAA patients compared to non-aneurysmal patients [89]. Interestingly, 
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UCN2 protein expression within the AAA wall was mostly co-located with infiltrating T-
lymphocytes and neutrophils [101], suggesting that these infiltrated immune cells are the 
source of UCN2 production within the AAA wall. In keeping with that, it was observed that 
explant preparation from the dilated portion of AAA releases larger amount of UCN2 
compared to non-dilated proximal neck of the AAA [101]. These data demonstrate that 
UCN2 has a plausive role on AAA pathogenesis; however, do not provide information about 
its function, if beneficial or detrimental.  
In the cardiovascular system, UCNs have been shown to be key modulators of inflammation 
and apoptosis, critical mechanisms in AAA pathology. For instance, it was shown that pro-
inflammatory cytokines, such as TNFα and IFNγ, upregulated UCN1 protein expression in 
human umbilical vein endothelial cells, while UCN1 effectively attenuated the generation of 
ROS induced by Ang II [103]. In another study, it was found that UCN1 suppressed the LPS-
induced upregulation of MCP1 and ICAM1 in human endothelial cells [100]. Moreover, in 
human aortic smooth muscle cells, UCN1 suppressed Ang II-induced migration, inhibit cell 
proliferation without inducing apoptosis and enhance the activities of MMP2 and MMP9 
[100]. Others reported that UCN1 treatment inhibited cell proliferation and VEGF release in 
rat smooth muscle cells [104]. Accordingly, UCN2 decreased human vascular smooth muscle 
proliferation and increases IL-6 secretion in a dependent manner of CRFR2 [101]. Taken 
together these data indicate that UNCs modulate critical molecular pathways of AAA 
pathophysiology in a protective manner; however, the speculation about the potential of 
UNCs against AAA must be evaluated in future studies.   
 
Perspectives and Future Directions 
Overall, the discussion above demonstrates that there are no satisfactory data clearly 
indicating to a single pharmacological approach for the treatment of AAA. Moreover, 
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evidence points to emerging targets for which the real potential needs to be investigated. The 
following key topics should be considered: 
1) Despite the fact that statins and tetracyclines have been suggested by several pre-
clinical and clinical trials as interesting tools to attenuate AAA growth and rupture 
probability, conflicting data hamper the recommendation of such drugs in clinical 
practice. Therefore, large and well-controlled clinical trials are needed to assess the 
effectiveness of these drugs;  
2) Classical RAS blockers (ARBs and ACEi) appear to be promising agents in the 
treatment of AAA; however, the literature addressing the effectivity of ACEi and 
ARBs in human AAA is limited, and clinical trials are needed to assess its potential; 
3) The protective arm of the RAS (ACE2/Ang-(1-7)/Mas receptor), renin inhibitors, 
pharmacological inhibition of IL-1 and anti-angiogenic agents have emerged as 
potential molecular targets against AAA, however the mechanisms of action and 
effectivity of these targets must be further assessed; 
4) Few studies suggest UCNs have an important role on AAA pathophysiology, and its 
beneficial effects against AAA may arise from its anti-inflammatory and –anti-
apoptotic actions in the cardiovascular system. However, the number of published 
data is limited and the contribution of UNC, if benefic or detrimental, is still not clear 
shown. Further studies are needed to evaluate the direct actions of UCNs on AAA and 
assess its relevance and potential as a pharmacological tool to treat AAA.   
 
Conclusion  
Significant efforts have been made to identify new molecular targets able to retard AAA 
progression and reduced the risk of rupture. So far, there are no satisfactory data that clearly 
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point out to a specific treatment. Recently, promising candidates have been suggested but 
they required further investigation to assess its real potential.  
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